Helix BioPharma Announces $13.5 Million Private Placement



    


    
    AURORA, Ontario, Sept. 4 /CNW/ -- Helix BioPharma Corp. (TSX, FSE: "HBP"
/ OTCQX: "HXBPF") today announced that it has accepted subscriptions for the
purchase, by way of private placement, of a total of 6,625,000 units at $2.05
per unit, for gross proceeds totaling CDN$13,581,250.  The Company anticipates
closing the private placement by September 11, 2009.

    Each unit consists of one common share and one common share purchase
warrant, with each common share purchase warrant entitling the holder to
purchase one common share of the Company at a price of $2.87 for up to three
years after the closing date of the private placement.  Proceeds of the
placement will be used for working capital to support the Company's expanding
clinical trial initiatives.
    

    About Helix BioPharma Corp.

    
    Helix BioPharma Corp. is a biopharmaceutical company specializing in the
field of cancer therapy. The Company is actively developing innovative
products for the prevention and treatment of cancer based on its proprietary
technologies. Helix's product development initiatives include its novel
L-DOS47 new drug candidate and its Topical Interferon Alpha- 2b. Helix is
listed on the TSX and FSE under the symbol "HBP" and the OTCQX International
Market under the symbol "HXBPF".


    For further information contact:

    
    Investor & Media Relations
    Robert Flamm, Ph.D.                       Ian Stone
    Russo Partners LLC                        Russo Partners LLC
    Tel: (212) 845-4226                       Tel: (619) 814-3510
    robert.flamm@russopartnersllc.com         Fax: (619) 955-5318
    www.russopartnersllc.com                  ian.stone@russopartnersllc.com

    
    This News Release contains certain forward-looking statements and
information regarding Helix BioPharma Corp. ("Helix" or the "Company"), its
proposed private placement and its development activities, which statements
and information can be identified by the use of forward looking terminology
such as "anticipate", "will", "next",  and "developing".  Helix's actual
results could differ materially from these forward-looking statements and
information as a result of numerous risk factors, including without
limitation, the risk that the proposed private placement may not close as
anticipated or at all; that proceeds of the placement may be used for purposes
other than those currently intended; research & development risks, which may
result in the Company's termination of either or both of its current product
development programs; and Helix's continuing need for additional future
capital to carry on its business.    Such risks and uncertainties, and others
affecting the Company, are more fully described in the Company's latest MD&A,
Form 20-F, and other reports filed with the Canadian Securities Regulatory
Authorities and the U.S. S.E.C. from time to time at www.sedar.com, and
www.sec.gov/edgar.shtml, respectively.  Forward-looking statements and
information are based on the beliefs, assumptions, opinions and expectations
of Helix's management at the time they are made, and Helix does not assume any
obligation to update any forward-looking statement or information should those
beliefs, assumptions, opinions or expectations change, except as required by
law.
    




    




For further information:

For further information: Investor & Media Relations, Robert Flamm,
Ph.D., +1-212-845-4226, robert.flamm@russopartnersllc.com; or Ian Stone,
+1-619-814-3510, +1-619-955-5318, ian.stone@russopartnersllc.com, both of
Russo Partners LLC Web Site: http://www.russopartnersllc.com

Organization Profile

HELIX BIOPHARMA CORP.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890